Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment

American Journal of Hypertension

Volumn 25, Issue 7, 2012, Pages 818-826

  Sarzani, Riccardo ^a   Guerra, Federico ^a   Mancinelli, Lucia ^a   Buglioni, Alessia ^a   Franchi, Eliana ^a   Dess Fulgheri, Paolo ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

aldosterone; angiotensin receptor blockers; angiotensinconverting enzyme inhibitors; antihypertensive therapy; blood pressure; essential hypertension; hypertension; obesity; renin angiotensin system

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MINERALOCORTICOID RECEPTOR; THIAZIDE DIURETIC AGENT;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL TRIAL; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OBESITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY;

EID: 84863721734     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.47     Document Type: Article

References (36)

1. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113:898-918.
2. MacMahon S, Alderman MH, Lindholm LH, Liu L, Sanchez RA, Seedat YK. Bloodpressure-related disease is a global health priority. Lancet 2008; 371:1480-1482. (Pubitemid 351626171)
3. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52:818-827.
4. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001; 79:21-29. (Pubitemid 32250020)
5. Yasue S, Masuzaki H, Okada S, Ishii T, Kozuka C, Tanaka T, Fujikura J, Ebihara K, Hosoda K, Katsurada A, Ohashi N, Urushihara M, Kobori H, Morimoto N, Kawazoe T, Naitoh M, Okada M, Sakaue H, Suzuki S, Nakao K. Adipose tissuespecific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 2010; 23:425-431.
6. Sarzani R, Salvi F, Dessí-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26:831-843. (Pubitemid 351540757)
7. Landsberg L, Troisi R, Parker D, Young JB, Weiss ST. Obesity, blood pressure, and the sympathetic nervous system. Ann Epidemiol 1991; 1:295-303.
8. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43:358-363. (Pubitemid 38174139)
9. Jeon JH, Kim KY, Kim JH, Baek A, Cho H, Lee YH, Kim JW, Kim D, Han SH, Lim JS, Kim KI, Yoon do Y, Kim SH, Oh GT, Kim E, Yang Y. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008; 22:1502-1511. (Pubitemid 351656790)
10. Ramachandran S, Vasan MD, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351:33-41.
11. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93:2566-2571. (Pubitemid 352008521)
12. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91:457-465. (Pubitemid 12203819)
13. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010; 23:1170-1178.
14. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29:13-21. (Pubitemid 32236891)
15. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3:486-492. (Pubitemid 47313030)
16. Otani H, Otsuka F, Inagaki K, Suzuki J, Miyoshi T, Kano Y, Goto J, Ogura T, Makino H. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008; 149:2816-2825. (Pubitemid 351724501)
17. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
18. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10:348-354.
19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143-3421.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
21. Bailey KR, Grossardt BR, Graves JW. Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates. Hypertension 2008; 51:841-847. (Pubitemid 351654693)
22. Tuck ML. Does aldosterone modulate central control of blood pressure? J Hypertens 2002; 20:1079-1080. (Pubitemid 34913622)
23. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35:1270-1277. (Pubitemid 30413663)
24. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304:930-933. (Pubitemid 11101080)
25. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 2008; 86:729-734.
26. Tomaschitz A, Maerz W, Pilz S, Ritz E, Scharnagl H, Renner W, Boehm BO, Fahrleitner-Pammer A, Weihrauch G, Dobnig H. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol 2010; 55:2171-2180.
27. Azizi M, Guyene TT, Chatellier G, Wargon M, Ménard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29:634-640. (Pubitemid 27074730)
28. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92:4472-4475. (Pubitemid 350074772)
29. Guerra F, Mancinelli L, Angelini L, Fortunati M, Rappelli A, Dessí-Fulgheri P, Sarzani R. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS ONE 2011; 6:e16630.
30. Pratt JH. A not-so-modest proposal that a "modest" increase in aldosterone causes hypertension and more. Hypertension 2008; 51:39-40. (Pubitemid 350307099)
31. Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur Heart J 1995; 16(Suppl N):79-85. (Pubitemid 26082325)
32. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006; 27:47-72. (Pubitemid 43228238)
33. Sarzani R, Dessí-Fulgheri P, Rappelli A. Angiotensin receptor blockers: dose does matter. J Hypertens 2007; 25:1921-1926.
34. Weir MR, Hollenberg NK, Remuzzi G, Zappe DH, Meng X, Parving HH. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. J Hypertens 2011; 29: 2031-2037.
35. Mars JC. Spironolactone management of arterial hypertension. Ann Pharmacother 2010; 44:1762-1769.
36. Pouleur AC, Uno H, Prescott MF, Desai A, Appelbaum E, Lukashevich V, Smith BA, Dahl? B, Solomon SD. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2011; e-pub ahead of print 11 July 2011.